Erythrina cristagalli lectin-reactive alpha-fetoprotein- E2: a marker of hepatocellular carcinoma and other malignancies.
A newly isolated lectin Erythrina cristagalli (ECL) was tested for separation of human alpha-fetoprotein ( AFP) glycoforms by affinity electrophoresis at 0.5 mg/ml and separated AFP bands were detected by antibody-affinity blotting. Three AFP bands, AFP-E1, AFP- E2 and AFP- E3 in order of increasing affinity, were obtained. Sera from control patients with chronic hepatitis and cirrhosis gave a major band of AFP-E1 and a minor or trace band of AFP- E2 (3.4 +/- 2.3%), while those from patients with mostly advanced hepatocellular carcinomas had increased proportions of AFP- E2 band (16.6 +/- 10.2%). With a cutoff level of 8% (mean + 2SD of AFP- E2 for controls), the sensitivity for hepatocellular carcinoma was 72% at a specificity of 100%. Gastrointestinal tumors had much higher percentages of AFP- E2 and occasionally positive AFP- E3. Most of the yolk sac tumors examined showed AFP- E3 in addition to AFP- E2, although AFP- E3 was a minor band. Thus, AFP- E2 is potentially a clinically useful marker for differentiation of increased AFP in hepatocellular carcinoma and other malignancies from that in precancerous chronic hepatitis or cirrhosis.[1]References
- Erythrina cristagalli lectin-reactive alpha-fetoprotein-E2: a marker of hepatocellular carcinoma and other malignancies. Kamei, M., Misawa, A., Arai, J., Kamakura, K., Taketa, K. Int. J. Biol. Markers (1998) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
